Interpace Biosciences Announces Preliminary Unaudited Third Quarter 2026 Revenue

INTERPACE BIOSCIENCES, INC. (IDXG) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Interpace Biosciences Announces Preliminary Unaudited Third Quarter 2026 Revenue ● Preliminary Q3 2026 revenue expected to range from $10.1 million to $10.4 million ● Expected quarter-over-quarter growth of approximately 11% to 14% compared with Q2 2026 ● Expected ye

Event · Earnings
Original reporting
Published Oct 15, 2026, 10:10 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 15, 2026, 10:11 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$IDXG
Bullish
medium confidence
Mentioned
$IDXG
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$IDXGBullishMed
01

Why it matters

The preliminary revenue guidance signals continued growth, which may attract short‑term buying interest ahead of the final earnings release.

02

Market read

Micro‑cap biotech earnings guidance; relevant for traders focused on biotech earnings momentum.

03

What to watch

Potential delays in assay roll‑outs or reimbursement issues could dampen revenue growth.

Relevance 7/10Novelty 7/10Timing: pre‑market today

Background

Interpace Biosciences (NASDAQ: IDXG) provides thyroid diagnostic tests and is emerging in personalized medicine.

Company-level read

Ticker impact

$IDXGBullishMedium confidence
Context

Interpace Biosciences announced preliminary Q3 2026 revenue of $10.1M‑$10.4M, up ~11%‑14% QoQ.

Expected impact

likely slight upward pressure as market prices in higher revenue expectations

Evidence & confidence

Revenue guidance exceeds prior quarter and shows growth; investors may bid the stock higher pending final results.

Market effects

Positive signal for the molecular diagnostics sector, may lift peers.

Limited to U.S. biotech investors; no broader regional effect.

Minimal global impact; primarily a micro‑cap specific event.

Counterpoint

If final results fall short of the preliminary range, the stock could face a sharp correction.

Key entities

  • Interpace Biosciences, Inc.

    Issuer of the preliminary Q3 2026 revenue guidance.

Related articles

$IDXGMed

Interpace Biosciences Announces Second Quarter 2026 Financial and Business Results

INTERPACE BIOSCIENCES, INC. (IDXG) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Interpace Biosciences Announces Second Quarter 2026 Financial and Business Results ● Q2 Revenue of $9.1 million ● Q2 Income from Continuing Operations of $0.3 million ● Q2 Thyroid volume year-over-year increase of 6% ● Q2 Thyroid revenue year-over-year increase of 9%

$ZTEKFMed

Zentek Ltd. (ZTEKF): Financial results for FY2027

Zentek Ltd. (ZTEKF) furnished an SEC Form 6-K — earnings release. Zentek Q2 Fiscal 2027 Results News Release Zentek Strengthens Its Balance Sheet, Ends Second Quarter with $13.6 Million in Cash Working capital of $11.3 million at September 30, 2026, compared with a deficit of $1.3 million at March 31, 2026 Guelph, Ontario, November 16, 2026. Ze

$WBMedAI 8/10

Alibaba Is Pulling Back From This 10% Dividend Stock

Weibo (WB) missed Q3 revenue and earnings expectations, with advertising revenue from Alibaba (BABA) falling 33%. Shares dropped 4% premarket. GAAP net income fell 88.91%, operating cash flow turned negative, and long-term loans were reclassified as current. The dividend yield is 10.6%, but earnings are declining. CEO Gaofei Wang highlighted AI efforts, but ad budgets remain a concern.

$SLSHighAI 9/10

SELLAS Gets A REGAL Boost As Immunotherapeutic Cancer Vaccine Trial Meets Primary Endpoint

SELLAS Life Sciences (SLS) reported positive Phase 3 REGAL trial results for its cancer vaccine, Galinpepimut-S (GPS), meeting the primary endpoint of overall survival. GPS reduced the risk of death by 41% compared to standard treatment, with median OS of 24.0 months vs. 14.7 months. The company plans to discuss an accelerated FDA filing pathway and aims for a BLA submission in early 2027. Shares surged over 255% in premarket trading.